



## **Ventripoint Appoints Nicolas Coutin to Oversee Clinical Affairs**

**Toronto, Ontario – April 8, 2025** – Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) today announced that it has appointed Nic Coutin, PhD. to oversee Clinical Affairs. In this role he will be providing leadership to the Company's ongoing research, translational science, and clinical studies. Nicolas will report directly to Hugh MacNaught, President and CEO.

Dr. Coutin was part of the partnering team at AbCellera which built industry-leading capabilities through partnerships with the top tier of biotech and pharma industry partners. His experience includes leading the Venture and core programming team at Creative Destruction Lab, where, with his team, he delivered an objectives-based program for massively scalable, seed-stage, science- and technology-based companies.

"Nic has experience and a strong understanding of translational programs." said Ventripoint's CEO Hugh MacNaught. "His experience supporting the advancement of innovation from research to the clinic will enable us to build stronger relationships with our clinical advisors and collaborators."

Coutin added: "Ventripoint's decades of research and development have positioned it become the new standard for rapidly and robustly measuring heart function. Strengthening the clinical-evidence base will support broader clinical use of Ventripoint's VMS+™ V4.0. I look forward to working with the team to expand the application of this differentiated technology to numerous cardiac indications."

### **For further information, please contact:**

Hugh MacNaught

[hmacnaught@ventripoint.com](mailto:hmacnaught@ventripoint.com)

(604) 671-4201

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves



as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

### **Forward Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.